255 related articles for article (PubMed ID: 30328618)
1. What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
Curto-Garcia N; Ianotto JC; Harrison CN
Br J Haematol; 2018 Oct; 183(1):23-34. PubMed ID: 30328618
[TBL] [Abstract][Full Text] [Related]
2. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
Barosi G; Rosti V; Bonetti E; Campanelli R; Carolei A; Catarsi P; Isgrò AM; Lupo L; Massa M; Poletto V; Viarengo G; Villani L; Magrini U
PLoS One; 2012; 7(4):e35631. PubMed ID: 22536419
[TBL] [Abstract][Full Text] [Related]
3. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of prefibrotic myelofibrosis.
Rumi E; Sant'Antonio E; Boveri E; Pietra D; Cavalloni C; Roncoroni E; Astori C; Arcaini L;
Expert Rev Hematol; 2018 Jul; 11(7):537-545. PubMed ID: 29862872
[TBL] [Abstract][Full Text] [Related]
5. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
[TBL] [Abstract][Full Text] [Related]
6. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM
Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
[TBL] [Abstract][Full Text] [Related]
7. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany.
Schmidt A; Bernhardt C; Bürkle D; Fries S; Hannig CV; Jentsch-Ullrich K; Josting A; Kreher S; Reiser M; Steinmetz HT; Tesch H; Terner S; Schulte A; Crodel CC; Palandri F; Heidel FH
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7197-7206. PubMed ID: 36884118
[TBL] [Abstract][Full Text] [Related]
9. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.
Vachhani P; Loghavi S; Bose P
Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):413-426. PubMed ID: 38341324
[TBL] [Abstract][Full Text] [Related]
10. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
12. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.
Gianelli U; Vener C; Bossi A; Cortinovis I; Iurlo A; Fracchiolla NS; Savi F; Moro A; Grifoni F; De Philippis C; Radice T; Bosari S; Lambertenghi Deliliers G; Cortelezzi A
Mod Pathol; 2012 Sep; 25(9):1193-202. PubMed ID: 22627739
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
15. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
Thiele J; Kvasnicka HM
Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myeloproliferative disorders. The new WHO classification].
Thiele J; Kvasnicka HM
Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
[TBL] [Abstract][Full Text] [Related]
17. [Occurrence of myelofibrosis in individual types of chronic myeloproliferative diseases].
Adamkov M; Plank L; Szépe P
Bratisl Lek Listy; 1998 May; 99(5):240-4. PubMed ID: 9673037
[TBL] [Abstract][Full Text] [Related]
18. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
19. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
20. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
